UroGen Pharma (URGN) Tops Q2 EPS by 10c

UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($1.17), $0.10 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $13.03 million versus the consensus estimate of $10.21 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c